COMPANY

Diagonal Therapeutics

Keywords: rare disease rare diseases Hereditary Hemorrhagic Telangiectasia Pulmonary Arterial Hypertension DIAG723

Profile checked Oct 10, 2026

Timeline

Jun 4, 2026 Trial start Phase 1/Phase 2: DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia source ↗
Jan 8, 2026 Raise Private equity round — Series B: $125M (total, as published), announced Jan 8, 2026. Source: company's own press page. source ↗
Dec 4, 2025 Partnership Partnership / licensing announced Dec 4, 2025. Source: company's own press page. source ↗

Nov 30, 2027 (ESTIMATED) · Phase 1/Phase 2 · DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia · NCT07623525

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $125.0M. Last 2 years.

Jan 8, 2026 Private equity round — Series B: $125M (total, as published), announced Jan 8, 2026. Source: company's own press page. source ↗
Dec 4, 2025 Partnership / licensing announced Dec 4, 2025. Source: company's own press page. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07623525	DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia	Phase 1/Phase 2	Recruiting	Jun 4, 2026	Nov 30, 2027 (estimated)

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of Atlas Venture (captured Oct 12, 2026). portfolio page ↗